Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03730948 · ClinicalTrials.gov registry record · Phase 1
DC Vaccine in Colorectal Cancer
A Phase 1 study, sponsored by University of Pennsylvania.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT03730948: Clinical Trial Phase 1 study, sponsored by University of Pennsylvania.
NCT03730948 is a Phase 1 study that was terminated before completion, run by University of Pennsylvania. The registered enrollment target is 4 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03730948, a Phase 1 study, was terminated before completion, sponsored by University of Pennsylvania.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
This is a pilot study to assess the safety and tolerability, as well as the immune response rate, of mDC3 vaccine in patients with colorectal cancer.
Interventions
- BIOLOGICAL DC vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2019-03-12 |
| Est. Completion | 2022-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03730948
The ClinicalTrials.gov registry entry for NCT03730948 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DC vaccine is the first listed.
NCT03730948 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03730948 about?
NCT03730948 is a clinical study titled "DC Vaccine in Colorectal Cancer". This is a pilot study to assess the safety and tolerability, as well as the immune response rate, of mDC3 vaccine in patients with colorectal cancer.
What is the current status of trial NCT03730948?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2019-03-12. Estimated completion is 2022-12-01.
What interventions are being tested in trial NCT03730948?
The interventions under investigation include: DC vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT03730948?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.